After-Hours Movers 05/10: (ARNA) (OREX) (AVG) Higher; (PEIX) (DAR) (PBTH) (ASYS) (JPM) Lower
Tweet
Share
E-mail
Get Alerts ARNA Hot Sheet
Join SI Premium – FREE
Arena Pharma (Nasdaq: ARNA) 93% HIGHER; FDA Advisory panel backs Arena's, Eisai's lorcaserin diet pill. Click here to see the full report.
PACIFIC ETHANOL (NASDAQ: PEIX) 17% LOWER; reported Q1 EPS of ($0.06), versus ($0.02) reported last year. Revenue for the quarter came in at $197.7 million versus the consensus estimate of $173 million.
Orexigen (Nasdaq: OREX) 12% HIGHER; Arena won FDA panel backing for its lorcaserin drug candidate.
Darling International (NYSE: DAR) 12% LOWER; reported Q1 EPS of $0.24, $0.06 worse than the analyst estimate of $0.30. Revenue for the quarter came in at $387.1 million versus the consensus estimate of $410.78 million.
PROLOR Biotech, Inc. (AMEX: PBTH) 11% LOWER; announced plans to offer and sell shares of its common stock in an underwritten public offering.
Amtech Systems (NASDAQ: ASYS) 11% LOWER; reported Q2 EPS of ($0.54), $0.32 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $21.6 million versus the consensus estimate of $21.55 million. Sees FY2012 revenue of $18-$20 million, versus the consensus of $27 million.
Avg Technologies (NYSE: AVG) 10% HIGHER; reported Q1 EPS of $0.34, versus $0.38 reported last year. Revenue for the quarter came in at $83 million versus the consensus estimate of $60.8 million. Sees Q2 2012 EPS of $0.26-$0.26. Avg Technologies sees Q2 2012 revenue of $80-$82 million. Sees FY2012 EPS of $1.08-$1.14. Avg Technologies sees FY2012 revenue of $327-$335 million.
Greenway Medical Technologies (NYSE: GWAY) 10% HIGHER; reported Q3 EPS of $0.08, $0.04 better than the analyst estimate of $0.04. Revenue for the quarter came in at $32.9 million versus the consensus estimate of $28.54 million.
McDermott International, Inc. (NYSE: MDR) 8.5% HIGHER; reported Q1 EPS of $0.25, $0.10 better than the analyst estimate of $0.15. Revenue for the quarter came in at $727.7 million versus the consensus estimate of $834.83 million.
Roundys (NYSE: RNDY) 7.6% LOWER; reported Q1 EPS of $0.28, $0.02 better than the analyst estimate of $0.26. Revenue for the quarter came in at $938.2 million versus the consensus estimate of $929.4 million.
Codexis, Inc. (NASDAQ: CDXS) 7.6% LOWER; reported Q1 EPS of ($0.21), $0.04 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $31.1 million versus the consensus estimate of $30.85 million. For the full year 2012, Codexis forecasts revenues in line with or exceeding 2011 results. Codexis expects 2012 Adjusted EBITDA will be positive, and expects total cash burn to be in line with 2011 levels.
WuXi PharmaTech (NYSE: WX) 6% HIGHER; reported Q1 EPS of $0.28, $0.01 better than the analyst estimate of $0.27. Revenue for the quarter came in at $118 million versus the consensus estimate of $114.19 million. Sees Q2 2012 revenue of $124-$129 million, versus the consensus of $118.03 million.
JPMorgan (NYSE: JPM) 6% LOWER; says CIO unit has significant mark-to-market losses. Click here to read the full report.
Nordstrom, Inc. (NYSE: JWN) 5.7% LOWER; reported Q1 EPS of $0.70, $0.05 worse than the analyst estimate of $0.75. Revenue for the quarter came in at $2.53 billion versus the consensus estimate of $2.52 billion. Same-store sales up 8.5%.
Dillards, Inc. (NYSE: DDS) 5.6% HIGHER; reported Q1 EPS of $1.89, $0.22 better than the analyst estimate of $1.67. Revenue for the quarter came in at $1.55 billion versus the consensus estimate of $1.53 billion.
Longwei Petroleum (NYSE: LPH) 4% LOWER; reported Q3 EPS of $0.47, $0.07 better than the analyst estimate of $0.40.
Nuance Communications, Inc. (NASDAQ: NUAN) 4% LOWER; reported Q2 EPS of $0.43, $0.02 better than the analyst estimate of $0.41. Revenue for the quarter came in at $417.7 million versus the consensus estimate of $412.64 million.
Molycorp (NYSE: MCP) 3.8% LOWER; reported Q1 EPS of $0.18, $0.05 better than the analyst estimate of $0.13. Revenue for the quarter came in at $84.47 million versus the consensus estimate of $116.22 million.
Citi (NYSE: C) 3.5% LOWER; the entire Banking sector is trading lower amid the JPMorgan headlines.
MBIA, Inc. (NYSE: MBI) 2.8% LOWER; reported Q1 EPS of $0.05, which may not compare with the analyst estimate of $0.13. Revenue for the quarter came in at $137 million versus the consensus estimate of $104.76 million. Adjusted Book Value (ABV), a non-GAAP measure, was $32.00 per share at March 31, 2012 compared with $34.50 per share at December 31, 2011.
Goldman Sachs (NYSE: GS) 2.7% LOWER; see Citi.
BofA (NYSE: BAC) 2.7% LOWER; see Citi.
Sothebys (NYSE: BID) 2.5% HIGHER; reported Q1 EPS of ($0.16), in-line with the analyst estimate of ($0.16). Revenue for the quarter came in at $105 million versus the consensus estimate of $94.2 million.
Morgan Stanley (NYSE: MS) 2.5% LOWER; see Citi.
FX Energy, Inc. (NASDAQ: FXEN) 2.3% HIGHER; reported Q1 EPS of $0.28, $0.30 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $8.6 million versus the consensus estimate of $8.75 million.
Wells Fargo (NYSE: WFC) 2% LOWER; see Citi.
Alexza Pharmaceuticals, Inc. (NASDAQ: ALXA) 2% LOWER; reported Q1 EPS of ($0.04), $0.04 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $1.88 million versus the consensus estimate of $1.3 million.
PACIFIC ETHANOL (NASDAQ: PEIX) 17% LOWER; reported Q1 EPS of ($0.06), versus ($0.02) reported last year. Revenue for the quarter came in at $197.7 million versus the consensus estimate of $173 million.
Orexigen (Nasdaq: OREX) 12% HIGHER; Arena won FDA panel backing for its lorcaserin drug candidate.
Darling International (NYSE: DAR) 12% LOWER; reported Q1 EPS of $0.24, $0.06 worse than the analyst estimate of $0.30. Revenue for the quarter came in at $387.1 million versus the consensus estimate of $410.78 million.
PROLOR Biotech, Inc. (AMEX: PBTH) 11% LOWER; announced plans to offer and sell shares of its common stock in an underwritten public offering.
Amtech Systems (NASDAQ: ASYS) 11% LOWER; reported Q2 EPS of ($0.54), $0.32 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $21.6 million versus the consensus estimate of $21.55 million. Sees FY2012 revenue of $18-$20 million, versus the consensus of $27 million.
Avg Technologies (NYSE: AVG) 10% HIGHER; reported Q1 EPS of $0.34, versus $0.38 reported last year. Revenue for the quarter came in at $83 million versus the consensus estimate of $60.8 million. Sees Q2 2012 EPS of $0.26-$0.26. Avg Technologies sees Q2 2012 revenue of $80-$82 million. Sees FY2012 EPS of $1.08-$1.14. Avg Technologies sees FY2012 revenue of $327-$335 million.
Greenway Medical Technologies (NYSE: GWAY) 10% HIGHER; reported Q3 EPS of $0.08, $0.04 better than the analyst estimate of $0.04. Revenue for the quarter came in at $32.9 million versus the consensus estimate of $28.54 million.
McDermott International, Inc. (NYSE: MDR) 8.5% HIGHER; reported Q1 EPS of $0.25, $0.10 better than the analyst estimate of $0.15. Revenue for the quarter came in at $727.7 million versus the consensus estimate of $834.83 million.
Roundys (NYSE: RNDY) 7.6% LOWER; reported Q1 EPS of $0.28, $0.02 better than the analyst estimate of $0.26. Revenue for the quarter came in at $938.2 million versus the consensus estimate of $929.4 million.
Codexis, Inc. (NASDAQ: CDXS) 7.6% LOWER; reported Q1 EPS of ($0.21), $0.04 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $31.1 million versus the consensus estimate of $30.85 million. For the full year 2012, Codexis forecasts revenues in line with or exceeding 2011 results. Codexis expects 2012 Adjusted EBITDA will be positive, and expects total cash burn to be in line with 2011 levels.
WuXi PharmaTech (NYSE: WX) 6% HIGHER; reported Q1 EPS of $0.28, $0.01 better than the analyst estimate of $0.27. Revenue for the quarter came in at $118 million versus the consensus estimate of $114.19 million. Sees Q2 2012 revenue of $124-$129 million, versus the consensus of $118.03 million.
JPMorgan (NYSE: JPM) 6% LOWER; says CIO unit has significant mark-to-market losses. Click here to read the full report.
Nordstrom, Inc. (NYSE: JWN) 5.7% LOWER; reported Q1 EPS of $0.70, $0.05 worse than the analyst estimate of $0.75. Revenue for the quarter came in at $2.53 billion versus the consensus estimate of $2.52 billion. Same-store sales up 8.5%.
Dillards, Inc. (NYSE: DDS) 5.6% HIGHER; reported Q1 EPS of $1.89, $0.22 better than the analyst estimate of $1.67. Revenue for the quarter came in at $1.55 billion versus the consensus estimate of $1.53 billion.
Longwei Petroleum (NYSE: LPH) 4% LOWER; reported Q3 EPS of $0.47, $0.07 better than the analyst estimate of $0.40.
Nuance Communications, Inc. (NASDAQ: NUAN) 4% LOWER; reported Q2 EPS of $0.43, $0.02 better than the analyst estimate of $0.41. Revenue for the quarter came in at $417.7 million versus the consensus estimate of $412.64 million.
Molycorp (NYSE: MCP) 3.8% LOWER; reported Q1 EPS of $0.18, $0.05 better than the analyst estimate of $0.13. Revenue for the quarter came in at $84.47 million versus the consensus estimate of $116.22 million.
Citi (NYSE: C) 3.5% LOWER; the entire Banking sector is trading lower amid the JPMorgan headlines.
MBIA, Inc. (NYSE: MBI) 2.8% LOWER; reported Q1 EPS of $0.05, which may not compare with the analyst estimate of $0.13. Revenue for the quarter came in at $137 million versus the consensus estimate of $104.76 million. Adjusted Book Value (ABV), a non-GAAP measure, was $32.00 per share at March 31, 2012 compared with $34.50 per share at December 31, 2011.
Goldman Sachs (NYSE: GS) 2.7% LOWER; see Citi.
BofA (NYSE: BAC) 2.7% LOWER; see Citi.
Sothebys (NYSE: BID) 2.5% HIGHER; reported Q1 EPS of ($0.16), in-line with the analyst estimate of ($0.16). Revenue for the quarter came in at $105 million versus the consensus estimate of $94.2 million.
Morgan Stanley (NYSE: MS) 2.5% LOWER; see Citi.
FX Energy, Inc. (NASDAQ: FXEN) 2.3% HIGHER; reported Q1 EPS of $0.28, $0.30 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $8.6 million versus the consensus estimate of $8.75 million.
Wells Fargo (NYSE: WFC) 2% LOWER; see Citi.
Alexza Pharmaceuticals, Inc. (NASDAQ: ALXA) 2% LOWER; reported Q1 EPS of ($0.04), $0.04 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $1.88 million versus the consensus estimate of $1.3 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citigroup set to join top banks in Anthropic IPO - Bloomberg
- BofA Securities Starts Mobility Global (MBGL) at Neutral
- Wells Fargo Upgrades Portland General Electric Company (POR) to Overweight
Create E-mail Alert Related Categories
Special ReportsRelated Entities
JPMorgan, Citi, Morgan Stanley, American Technology Research, After-Hours Movers, Wells FargoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
